Skip to main content
Premium Trial:

Request an Annual Quote

PathAI, Discovery Life Sciences Form Biospecimen Analysis Alliance

NEW YORK — PathAI has signed an agreement to help Discovery Life Sciences develop an artificial intelligence-based tissue analysis panel for use in translational research and biomarker discovery, the companies said on Thursday.

The panel, the companies said, will be offered to Discovery's biopharmaceutical partners. 

As part of the deal, Discovery will also begin using PathAI's AISight image management system throughout its biospecimens business. AISight includes Boston-based PathAI's newly launched Artifact Detect digital pathology artifact detection tool and TumorDetect tumor assessment tool.

Financial and other terms were not disclosed.

"This partnership will significantly enhance our ability to deliver precise, reliable, and timely insights, ultimately advancing the discovery and development of therapies and diagnostics that improve patient outcomes," Discovery CEO Greg Herrema said in a statement.

In 2024, Huntsville, Alabama-based Discovery struck a deal to add Bio-Techne's Comet spatial biology platform to its suite of specialty laboratory services.

In late 2021, PathAI began working with Akoya Biosciences — now part of Quanterix — to identify and validate biomarkers for predicting patient response to cancer immunotherapies.